Additional indications classified as “Other” (9.6%) in Table 1 included chronic pelvic pain, ovarian cyst with a history of breast cancer, a BRCA1 mutation, uterine cavity polyp, and lower urinary tract symptoms. This evidence concerns the gene BRCA1 and breast carcinoma.